Overview
Biopharmaceutical firm's 2025 collaboration revenue beat analyst expectations
Net income for 2025 showed a slight beat against analyst estimates
Operating income for 2025 beat analyst expectations
Outlook
Immatics expects anzu-cel BLA submission in 1H 2027 and launch in 2H 2027
Company plans IMA402/IMA401 combination trial in lung cancer in 2026
Immatics to present IMA203CD8 Phase 1a data in ovarian cancer in 1H 2026
Result Drivers
PRAME CELL THERAPY - Anzu-cel received Orphan Drug Designation from FDA for melanoma, with ongoing Phase 3 trial SUPRAME
SECOND-GENERATION THERAPY - IMA203CD8 shows promising data in gynecologic cancers, with Phase 1a data update planned
MODERNA COLLABORATION - Expanded collaboration with Moderna includes milestone payment and new mRNA-based TCER® development
Company press release: ID:nGNE16pLYW
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Collaboration Revenue | Beat | EUR 48.27 mln | EUR 37.82 mln (8 Analysts) |
FY Net Income | Slight Beat* | -EUR 196.45 mln | -EUR 197.06 mln (7 Analysts) |
FY Operating Income | Beat | -EUR 182.02 mln | -EUR 185.69 mln (7 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Immatics NV is $17.00, about 67% above its March 4 closing price of $10.18
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments